Released May 7, 2024, after the close
10-Q filed May 7, 2024, 37 days after period end · 0001558370-24-007041
Q1 2024 · 10-Q
Revenue$29.53M$29.53M +13.3% vs Q1 2023−17.5% vs Q4 2023
Net Income-$8.25M-$8.25M N/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$0.47-$0.47 N/M vs Q1 2023no prior Q4 2023 on file
Operating Income-$6,966,000N/M
Operating Cash Flow-$5,013,000N/M
Margins · derived
Operating margin-23.6%+25.2 pt vs Q1 2023
Net margin-27.9%+24.0 pt vs Q1 2023
What the release said
The release
Same quarter
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Revenue | $29.53M | $26.07M | $16.74M | $81.02M |
| Net Income | -$8.25M | -$13.54M | -$27.45M | $39.50M |
| EPS Diluted | -$0.47 | -$0.08 | -$0.16 | $0.22 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Rigel Pharmaceuticals Inc · CIK 1034842 · Engraved from SEC EDGAR